human
coronavirus
hcov
consid
rel
harmless
respiratori
pathogen
past
howev
outbreak
sever
acut
respiratori
syndrom
sar
emerg
middl
east
respiratori
syndrom
mer
hcov
receiv
worldwid
attent
import
pathogen
respiratori
tract
infect
review
focus
epidemiolog
pathogenesi
clinic
characterist
among
sarscoronavirus
cov
merscov
hcov
infect
coronavirus
cov
larg
famili
singlestrand
rna
virus
infect
wide
varieti
anim
includ
human
caus
respiratori
enter
hepat
neurolog
diseas
largest
known
rna
virus
cov
divid
four
genera
alpha
beta
gammaand
deltacoronaviru
human
cov
caus
mainli
respiratori
tract
infect
current
six
human
coronavirus
hcov
identifi
includ
alphacov
betacov
sever
acut
respiratori
syndromecov
sarscov
middl
east
respiratori
syndromecov
merscov
although
hcov
identifi
decad
clinic
import
epidem
possibl
recogn
outbreak
sar
mer
sar
epidem
origin
anim
market
south
china
affect
peopl
death
countri
subsequ
world
health
organ
notifi
laboratoryconfirm
case
merscov
infect
least
death
august
found
countri
ill
report
saudi
arabia
articl
review
epidemiolog
pathogenesi
clinic
characterist
manag
patient
hcov
infect
although
cov
estim
circul
earth
centuri
origin
cov
remain
obscur
begin
outbreak
sar
mer
palm
civet
dromedari
camel
respect
suggest
natur
reservoir
two
hcov
virolog
genet
studi
indic
bat
reservoir
host
sarscov
merscov
use
palm
civet
dromedari
camel
intermediari
host
dissemin
human
recent
studi
propos
bat
cov
gene
sourc
alphacov
betacov
wherea
avian
cov
consid
gene
sourc
gammaand
deltacov
meanwhil
rodent
propos
reservoir
ancestor
lineag
betacov
includ
transmiss
anim
human
mechan
rout
transmiss
sarscov
merscov
remain
elus
direct
contact
intermediari
host
anim
consumpt
milk
urin
uncook
meat
hypothes
main
rout
sarscov
merscov
transmiss
humantohuman
transmiss
sarscov
merscov
occur
mainli
nosocomi
transmiss
mer
patient
individu
outbreak
link
hospit
similar
sar
patient
studi
republ
korea
reveal
index
patient
transmit
other
nonisol
day
hospit
bodi
temperatur
c
pulmonari
infiltr
lung
zone
transmiss
famili
member
occur
mer
case
sar
case
anoth
korean
studi
suggest
transmiss
mer
asymptomat
patient
rare
contrast
sarscov
merscov
direct
humantohuman
transmiss
report
four
hcov
sar
epidem
origin
anim
market
guangdong
provinc
china
subsequ
spread
countri
larg
outbreak
report
area
initi
epidem
nosocomi
acquisit
import
sar
health
care
worker
compris
report
case
china
canada
larg
major
mer
case
occur
arabian
peninsula
casecontrol
studi
compar
mer
patient
control
saudi
arabia
found
direct
contact
dromedari
week
ill
onset
associ
mershcov
ill
outbreak
countri
result
index
case
travel
histori
middl
east
north
africa
hcov
global
distribut
mainli
transmit
season
endem
way
usual
peak
winter
spring
case
occur
earli
summer
epidem
studi
communityacquir
pneumonia
cap
reveal
four
nonsar
nonmer
hcov
account
adult
cap
patient
pathogenesi
current
understand
pathogenesi
hcov
infect
still
limit
howev
sever
signific
differ
pathogenesi
exist
among
sarscov
merscov
hcov
critic
first
step
hcov
infect
entri
suscept
host
cell
combin
specif
receptor
spike
protein
protein
hcov
surfaceloc
trimer
glycoprotein
consist
two
subunit
ntermin
subunit
ctermin
subunit
subunit
special
recogn
bind
host
cell
receptor
region
respons
membran
fusion
date
wide
rang
divers
cellular
receptor
specif
recogn
domain
identifi
hcov
except
tabl
receptor
sarscov
surfac
molecul
local
arteri
venou
endotheli
cell
arteri
smooth
muscl
cell
epithelia
small
intestin
respiratori
tract
respiratori
tract
express
epitheli
cell
alveoli
trachea
bronchi
bronchial
serou
gland
alveolar
monocyt
macrophag
homologu
ace
protein
key
enzym
reninangiotensin
system
play
protect
role
lung
failur
counterpart
ace
promot
lung
oedema
impair
lung
function
downregul
occur
sarscov
infect
believ
contribut
patholog
chang
lung
form
lung
damag
attenu
block
reninangiotensin
pathway
interestingli
also
employ
sar
receptor
cellular
entri
despit
markedli
differ
pathogen
diseas
cours
find
suggest
receptor
usag
may
factor
determin
sever
hcov
infect
dipeptidyl
peptidas
also
known
receptor
merscov
multifunct
cellsurfac
protein
wide
express
epitheli
cell
kidney
small
intestin
liver
prostat
activ
leukocyt
express
upper
respiratori
tract
epithelium
camel
human
respiratori
tract
mainli
express
alveoli
rather
nasal
caviti
conduct
airway
key
factor
activ
cell
immun
respons
costimulatori
signal
cell
could
indic
possibl
manipul
host
immun
system
human
aminopeptidas
n
cellsurfac
metalloproteas
intestin
lung
kidney
epitheli
cell
identifi
receptor
receptor
sialic
acid
current
receptor
identifi
interferon
ifn
famili
cytokin
includ
provid
first
line
defenc
viral
pathogen
initi
transcript
hundr
ifnstimul
gene
isg
antivir
immun
modulatori
cell
regulatori
function
delay
recognit
critic
hcov
surviv
replic
host
vitro
studi
show
sarscov
merscov
evolv
genet
mechan
delay
ifn
induct
dysregul
isg
effector
function
primari
human
airway
epitheli
cell
cultur
cell
cov
show
mark
induct
proinflammatori
cytokin
h
lack
product
innat
antivir
cytokin
tumour
necrosi
factor
tnf
compar
sarscov
data
suggest
merscov
attenu
innat
immun
induc
delay
proinflammatori
respons
human
lung
epitheli
cell
correl
diseas
sever
clinic
cours
date
evid
exist
hcov
abil
inhibit
ifn
product
regul
isg
express
decreas
abil
escap
innat
immun
respons
host
may
explain
gener
milder
clinic
diseas
associ
hcov
infect
genera
differenti
cell
line
suscept
speci
tropism
viral
replic
effici
hcov
correl
clinic
epidemiolog
characterist
compar
sarscov
hcov
merscov
much
broader
cell
line
tropism
tabl
chan
colleagu
test
cell
line
suscept
merscov
human
cell
line
found
significantli
increas
mean
viral
load
infect
includ
lower
airway
hfl
intestin
tract
liver
kidney
hek
neuron
monocyt
lymphocyt
histiocyt
cell
line
respiratori
intestin
liver
kidney
histiocyt
cell
line
also
show
viral
nucleoprotein
express
immunofluoresc
addit
high
viral
load
merscov
could
induc
cytopath
effect
earli
day
intestin
liver
cell
line
day
lower
respiratori
tract
cell
line
faster
induc
sarscov
find
could
partli
explain
appar
sever
clinic
present
higher
fatal
rate
mer
patient
diagnosi
sar
mer
base
comprehens
contact
travel
histori
precis
laboratori
test
current
diagnost
tool
includ
molecular
method
serolog
viral
cultur
common
diagnost
method
molecular
detect
rt
revers
transcript
pcr
realtim
rtpcr
use
rna
extract
respiratori
tract
sampl
nasopharyng
swab
sputum
deep
tracheal
aspir
bronchoalveolar
lavag
notabl
lower
respiratori
tract
sampl
usual
yield
significantli
higher
viral
load
genom
fraction
upper
respiratori
tract
sampl
consist
tissu
tropism
sensit
antibodi
detect
usual
lower
molecular
method
mostli
use
retrospect
diagnosi
antibodi
detect
interv
day
acut
convalesc
serum
sampl
requir
order
document
seroconvers
least
fourfold
rise
antibodi
titr
singl
sampl
collect
least
day
onset
symptom
requir
valid
serolog
consid
virolog
test
rtpcr
limit
infect
consid
late
cours
ill
day
viral
cultur
rel
time
labour
consum
cultur
much
use
initi
phase
emerg
epidem
diagnost
assay
clinic
avail
furthermor
viral
cultur
also
employ
vitro
vivo
antivir
vaccin
evalu
studi
antigen
detect
assay
anoth
potenti
diagnost
tool
confirm
sarscov
merscov
infect
recommend
current
guidelin
sar
mer
present
spectrum
diseas
sever
rang
flulik
symptom
acut
respiratori
distress
syndrom
ard
clinic
characterist
compar
sar
mer
patient
seen
tabl
age
underli
diseas
signific
independ
predictor
variou
advers
outcom
sar
sar
case
mainli
seen
young
healthi
individu
wherea
half
case
merscov
infect
occur
individu
older
year
compar
sar
patient
preexist
chronic
ill
diabet
hypertens
chronic
renal
failur
chronic
heart
diseas
chronic
pulmonari
diseas
frequent
mer
patient
clinic
symptom
admiss
includ
fever
cough
myalgia
short
breath
sar
mer
patient
symptom
upper
respiratori
tract
infect
sore
throat
also
frequent
atyp
symptom
diarrhoea
vomit
develop
sar
mer
patient
hcov
infect
peopl
age
group
season
caus
sever
lower
respiratori
tract
infect
primarili
frail
patient
neonat
elderli
chronic
underli
diseas
immunosuppress
extrem
age
increas
risk
sever
hcov
infect
associ
death
rate
acut
kidney
injuri
aki
signific
characterist
sar
mer
patient
one
studi
report
sar
patient
acut
renal
impair
proteinuria
aki
much
common
mer
patient
occur
mechan
high
aki
incid
sar
mer
patient
well
clarifi
preexist
comorbid
condit
direct
viral
involv
kidney
may
contribut
develop
aki
sinc
receptor
sarscov
merscov
express
high
level
kidney
function
impair
cell
receptor
viral
bind
may
contribut
risk
aki
elev
creatinin
kinas
ck
valu
ul
observ
sar
patient
suggest
rhabdomyolysi
may
also
contribut
cardin
differ
mer
sar
frequenc
cardiovascular
involv
despit
high
lethal
shock
distinctli
unusu
sar
late
stage
hypotens
like
result
bacteri
superinfect
contrast
need
vasopressor
therapi
much
common
mer
one
seri
need
vasopressor
independ
risk
factor
death
intens
care
unit
icu
odd
ratio
confid
interv
p
multiorgan
involv
seldom
report
endem
hcov
infect
despit
occasion
fatal
pneumonia
highli
immunocompromis
patient
haematolog
abnorm
thrombocytopenia
lymphopenia
common
sar
mer
patient
thrombocytopenia
lymphopenia
may
predict
fatal
outcom
merscov
patient
laboratori
find
includ
airspac
opac
main
radiograph
featur
sar
patient
one
retrospect
studi
initi
chest
radiograph
abnorm
sar
patient
show
airspac
opac
patient
unilater
focal
involv
either
unilater
multifoc
bilater
involv
lower
lung
zone
right
lung
commonli
involv
four
pattern
radiograph
progress
recogn
patient
type
initi
radiograph
deterior
peak
level
follow
radiograph
improv
occur
major
patient
type
fluctuat
radiograph
chang
seen
patient
type
static
radiograph
appear
patient
type
progress
radiograph
deterior
patient
contrast
common
radiograph
featur
mer
patient
groundglass
opac
consolid
da
et
al
report
groundglass
opac
common
abnorm
mer
patient
follow
consolid
meanwhil
type
radiograph
progress
patient
common
mer
patient
follow
type
patient
type
patient
type
radiograph
progress
observ
four
patient
pleural
effus
p
pneumothorax
p
type
radiograph
progress
p
frequent
mer
patient
die
compar
recov
patient
similar
radiograph
find
comput
tomographi
find
mer
patient
also
includ
groundglass
opac
consolid
combin
pleural
effus
note
case
associ
poor
prognosi
merscov
infect
outcom
shown
tabl
mer
case
progress
respiratori
failur
receiv
invas
mechan
ventil
therapi
sar
patient
occurr
aki
usag
vasopressor
therapi
also
frequent
mer
patient
comparison
sar
retrospect
analysi
vasopressor
therapi
propos
independ
risk
factor
death
icu
mer
demonstr
higher
case
fatal
rate
sar
differ
host
factor
age
underli
diseas
may
explain
differ
howev
differenti
cell
line
suscept
viral
replic
effici
abil
inhibit
ifn
product
receptor
characterist
may
also
respons
differ
outcom
sarscov
merscov
infect
compar
sar
mer
hcovsassoci
pneumonia
case
usual
rel
mild
symptom
recov
quickli
fatal
case
report
mainli
frail
patient
neonat
elderli
immunocompromis
patient
moment
specif
therapi
sarscov
merscov
hcov
infect
avail
symptomat
support
treatment
mainstay
therapi
patient
infect
hcov
number
agent
show
effect
vitro
andor
anim
model
may
improv
outcom
patient
tabl
current
commonli
prescrib
antivir
regimen
clinic
set
ribavirin
ifn
lopinavirritonavir
date
ribavirin
ribavirin
plu
variou
type
ifn
common
therapeut
intervent
tri
patient
sar
mer
ribavirin
nucleosid
analogu
wide
spectrum
antivir
activ
inhibit
viral
rna
synthesi
mrna
cap
use
alon
treatment
sar
clinic
effect
inconsist
although
vitro
studi
show
combin
give
agent
better
antivir
activ
clinic
effect
remain
controversi
ifn
import
host
defenc
virus
vitro
experi
ifn
product
effect
inhibit
sarscov
mrescov
best
antivir
activ
seen
tabl
previou
studi
shown
posit
impact
variou
ifn
aspect
treatment
sar
mer
patient
better
oxygen
satur
rapid
resolut
inflamm
effect
signific
outcom
like
hospit
stay
longterm
surviv
lopinavir
ritonavir
proteas
inhibitor
may
inhibit
proteas
merscov
modul
apoptosi
human
cell
addit
lopinavirritonavir
ribavirin
associ
improv
clinic
outcom
compar
ribavirin
alon
sar
patient
although
lopinavir
show
suboptim
effect
cytotox
concentr
merscov
vitro
lopinavirritonavir
experiment
therapi
prove
improv
outcom
merscov
infect
anim
model
mycophenol
acid
mpa
anoth
potenti
therapeut
choic
frequent
use
immunosuppress
drug
prevent
reject
organ
transplant
inhibit
lymphocyt
prolifer
mpa
also
prevent
replic
viral
rna
vitro
studi
show
mpa
strong
inhibit
activ
merscov
howev
use
nonhuman
primat
model
show
mpatreat
anim
develop
sever
andor
fatal
diseas
higher
mean
viral
load
untreat
anim
passiv
immunotherapi
use
convalesc
phase
human
plasma
also
use
treatment
sar
mer
exploratori
metaanalysi
found
convalesc
plasma
decreas
mortal
sarscov
patient
administ
within
day
ill
network
use
convalesc
plasma
treatment
mer
case
current
form
test
safeti
efficaci
feasibl
corticosteroid
use
extens
sar
outbreak
gener
combin
ribavirin
lesson
sar
show
corticosteroid
treatment
associ
higher
subsequ
plasma
viral
load
increas
complic
varieti
agent
includ
antivir
peptid
monoclon
antibodi
cell
viral
proteas
inhibitor
antivir
shown
effect
vitro
andor
anim
model
clinic
trial
agent
await
pandem
potenti
hcov
remain
threat
public
health
activ
surveil
prudent
specif
treatment
current
avail
hcov
research
pathogenesi
hcov
infect
order
find
appropri
target
treatment
need
immunosuppress
pneumonia
patient
nonsar
nonmer
hcov
includ
differenti
diagnosi
yudong
yin
md
infecti
diseas
clinic
microbiolog
physician
beij
chaoyang
hospit
affili
capit
medic
univers
beij
china
activ
involv
research
aetiolog
communityacquir
pneumonia
particular
interest
atyp
pathogen
especi
mycoplasma
richard
g
wunderink
md
pulmonari
critic
care
physician
northwestern
univers
feinberg
school
medicin
chicago
il
longstand
interest
diagnosi
pneumonia
particularli
sever
communityacquir
pneumonia
site
princip
investig
recent
complet
us
center
diseas
control
preventionsponsor
epidemiolog
pneumonia
commun
epic
studi
